Trial Profile
Phase I Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 21 Jan 2017 Results of circulating tumor cells cohort from patients enrolled in two (NCT01008917, NCT01687673) trials (n=36) presented at the 2017 Gastrointestinal Cancers Symposium